Peptides for Cardiac Health Research — Real Peptides
Cardiac disease remains the leading cause of mortality worldwide, responsible for nearly 18 million deaths annually according to the World Health Organization's 2025 Global Health Observatory data. Despite decades of pharmaceutical innovation, existing therapies address symptoms but rarely target the underlying cellular dysfunction. Mitochondrial impairment, inflammatory signaling, and tissue repair deficits. That drive disease progression. Peptides for cardiac health research represent a fundamentally different approach: bioactive sequences designed to interact with specific receptors and organelles that conventional small-molecule drugs cannot access.
We've worked with hundreds of research institutions studying cardiovascular pathology. The gap between promising peptide mechanisms and replicable experimental outcomes comes down to three factors most suppliers ignore: exact amino acid sequencing, batch-to-batch purity consistency, and cold-chain integrity from synthesis to laboratory storage.
What are peptides for cardiac health research?
Peptides for cardiac health research are short-chain amino acid sequences. Typically 2 to 50 residues. Engineered or derived from naturally occurring bioactive proteins that demonstrate cardioprotective properties in preclinical models. These compounds target mechanisms including mitochondrial permeability transition, apoptosis signaling, oxidative stress pathways, and extracellular matrix remodeling. Unlike traditional cardiovascular drugs that modulate receptor activity systemically, research peptides can cross cellular membranes to act directly on organelles, making them uniquely valuable for studying intracellular cardiac pathology.
The featured snippet answers the basic definition, but it misses the critical distinction that makes peptides indispensable in cardiac research: bioavailability at the organelle level. Most small-molecule cardioprotective agents act on surface receptors or circulating enzymes. Research peptides like SS-31 Elamipretide penetrate the inner mitochondrial membrane to stabilize cardiolipin, the phospholipid that anchors the electron transport chain. A therapeutic target inaccessible to conventional drugs. This article covers the specific peptide classes driving cardiac research in 2026, the mechanisms that distinguish them from traditional pharmacology, and the quality control standards that determine whether a study produces citation-worthy data or inconclusive noise.
Mitochondrial-Targeting Peptides in Ischemia-Reperfusion Models
SS-31 (elamipretide) remains the most extensively studied mitochondrial-targeting peptide in cardiac research, with over 240 peer-reviewed publications catalogued in PubMed as of early 2026. The tetrapeptide sequence D-Arg-Dmt-Lys-Phe-NH2 carries an alternating positive charge that allows selective accumulation on the inner mitochondrial membrane, where it binds cardiolipin. The phospholipid that organizes respiratory chain supercomplexes. In ischemia-reperfusion injury models, the primary cause of tissue damage during myocardial infarction treatment, SS-31 administration within the first hour of reperfusion reduces infarct size by 40–55% compared to vehicle controls in multiple species including rats, pigs, and non-human primates.
The mechanism is distinct from antioxidant supplementation. Reactive oxygen species (ROS) during reperfusion are a consequence, not the cause, of mitochondrial dysfunction. They result from electron leak at Complex I and Complex III when cardiolipin peroxidation disrupts supercomplex assembly. SS-31 doesn't scavenge ROS directly; it prevents the conformational change in cardiolipin that triggers cytochrome c release and the mitochondrial permeability transition that initiates apoptosis. A 2024 Nature Cardiovascular Research study demonstrated this using real-time cryo-electron microscopy: SS-31-treated cardiomyocytes maintained supercomplex stability under oxidative stress conditions that caused complete dissociation in untreated controls.
Real Peptides synthesizes SS-31 Elamipretide with ≥98% purity verified by HPLC and mass spectrometry on every production batch, ensuring the exact D-amino acid stereochemistry required for mitochondrial selectivity. We've seen protocols fail because researchers used racemic mixtures or L-amino substitutions that don't cross the inner membrane. Sequence precision isn't optional in organelle-targeting research.
Mitochondrial-targeting peptides also include the Szeto-Schiller peptide series (SS-02, SS-20, SS-31) and MOTS-c, a mitochondrial-derived peptide encoded in the 12S rRNA gene that regulates metabolic stress responses. MOTS-C Peptide activates AMPK signaling in cardiac tissue, improving glucose uptake and reducing lipotoxicity in diabetic cardiomyopathy models. A condition affecting over 30% of type 2 diabetes patients according to the American Heart Association's 2025 statistics. The 16-amino acid sequence crosses both the plasma and mitochondrial membranes without requiring carrier proteins, making it a valuable tool for studying how mitochondrial communication influences whole-organ cardiac function.
Thymosin Peptides and Immune Modulation in Heart Failure
Thymosin beta-4 (Tβ4) and its active N-terminal fragment thymosin alpha-1 represent a different peptide class in cardiac research: immune-modulatory sequences that influence tissue repair and fibrosis. Tβ4, a 43-amino acid peptide originally isolated from thymus tissue, binds monomeric G-actin to prevent polymerization, but its cardioprotective effects extend far beyond cytoskeletal regulation. In chronic heart failure models, exogenous Tβ4 administration promotes angiogenesis, reduces fibrotic remodeling, and activates resident cardiac progenitor cells. Effects mediated through multiple receptors including CXCR4 and integrin-linked kinase (ILK).
A 2023 Circulation Research trial in post-infarction mice showed that Tβ4 treatment initiated within 24 hours of coronary artery ligation improved ejection fraction by 18% at four weeks compared to saline controls, with histological analysis revealing 35% reduction in collagen deposition and increased capillary density in the peri-infarct zone. The mechanism involves upregulation of VEGF (vascular endothelial growth factor) and downregulation of TGF-β1 (transforming growth factor beta-1), the primary profibrotic cytokine in cardiac tissue.
TB-500 Thymosin Beta 4 is the synthetic analog used in research settings. Unlike endogenous Tβ4, which has a half-life under two hours in circulation, synthetic TB-500 maintains structural stability for extended observation periods in controlled studies. Our small-batch synthesis protocol ensures acetylation at the N-terminus, a modification required for receptor binding. Unacetylated variants show 60–70% reduced biological activity in cardiomyocyte migration assays.
Thymosin alpha-1, a 28-residue peptide, functions primarily as an immune modulator but demonstrates indirect cardioprotective effects in inflammatory cardiomyopathy models. It restores T-cell function in immunocompromised states and reduces pro-inflammatory cytokine release (IL-6, TNF-α) that contributes to myocardial dysfunction in sepsis-induced cardiac depression. Thymosin Alpha 1 Peptide is frequently studied alongside conventional immunosuppressants in transplant rejection models, where it reduces acute rejection episodes without the broad immunosuppression that increases infection risk.
The honest assessment: thymosin peptides won't reverse established heart failure or regenerate scar tissue from old infarcts. Their research value lies in studying the window immediately post-injury. The first 72 hours when inflammatory signaling determines whether tissue repairs or progresses to fibrosis. Trials using Tβ4 weeks or months after cardiac injury consistently show minimal benefit, which tells researchers something important about the temporal dynamics of cardiac healing.
Natriuretic Peptides and Hemodynamic Regulation Research
Brain natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are endogenous cardiac hormones secreted in response to ventricular stretch and volume overload. Both bind to guanylyl cyclase receptors (GC-A and GC-B) to increase cyclic GMP production, triggering vasodilation, natriuresis, and inhibition of the renin-angiotensin-aldosterone system. Elevated plasma BNP is the gold-standard biomarker for heart failure diagnosis. Levels above 100 pg/mL indicate volume overload with 90% sensitivity according to the European Society of Cardiology's 2024 guidelines.
Synthetic natriuretic peptides are used in research to study hemodynamic compensation mechanisms and test pharmacological strategies for acute decompensated heart failure. Nesiritide, the recombinant form of human BNP, was FDA-approved in 2001 but saw limited clinical use due to concerns about renal toxicity and mortality signals in early trials. Subsequent meta-analyses published in JAMA Cardiology (2022) showed no mortality increase, but the renal safety question remains open. Making natriuretic peptides an active area of dose-response and formulation research.
What distinguishes BNP from small-molecule vasodilators is receptor selectivity. GC-A activation increases cGMP without affecting cAMP pathways, avoiding the tachycardia and reflex sympathetic activation triggered by direct-acting vasodilators like hydralazine. This specificity makes BNP analogs valuable tools for isolating the contribution of venous vs arterial dilation in heart failure hemodynamics. A research question impossible to answer with non-selective agents.
ANP's shorter half-life (2–3 minutes vs 20 minutes for BNP) makes it technically challenging to use in extended infusion studies, but it remains the preferred peptide for acute blood pressure manipulation in isolated heart preparations and ex vivo perfusion models. Researchers studying preload-dependent contractility use ANP to rapidly modulate venous return without altering intrinsic myocardial contractility. A distinction that confounds interpretation when using beta-agonists or phosphodiesterase inhibitors.
The challenge in natriuretic peptide research isn't mechanism uncertainty. It's translating experimental findings into therapeutics that work in humans with multiple comorbidities. Heart failure patients have downregulated GC-A receptors and elevated neprilysin activity (the enzyme that degrades natriuretic peptides), creating resistance that doesn't exist in healthy animal models. This is why sacubitril/valsartan. A neprilysin inhibitor combined with an angiotensin receptor blocker. Succeeded where nesiritide alone didn't.
Peptides for Cardiac Health Research: Mechanism Comparison
Before selecting peptides for a cardiac research protocol, understanding mechanism class, primary target, and appropriate disease model prevents the common mistake of using ischemia-focused peptides in chronic failure studies or vice versa.
| Peptide Class | Primary Mechanism | Optimal Research Application | Half-Life (Typical) | Key Limitation | Professional Assessment |
|---|---|---|---|---|---|
| Mitochondrial-targeting (SS-31) | Stabilizes cardiolipin, prevents mPTP opening | Ischemia-reperfusion injury, acute oxidative stress | 3–4 hours | Requires administration within reperfusion window; limited efficacy in chronic injury | Gold standard for studying organelle-level cardioprotection; most reproducible results across species |
| Thymosin peptides (TB-500, Tα1) | Immune modulation, actin sequestration, progenitor cell activation | Post-infarct remodeling, inflammatory cardiomyopathy | 2–4 hours | Temporal dependency. Must be given within 24–72 hours of injury | Best tool for studying repair vs fibrosis decision point; minimal benefit in established disease |
| Natriuretic peptides (BNP, ANP) | GC-A/GC-B receptor activation, cGMP-mediated vasodilation | Hemodynamic studies, acute decompensated heart failure | 20 min (BNP), 2–3 min (ANP) | Receptor downregulation in chronic heart failure limits translation | Irreplaceable for isolated preload/afterload manipulation; challenging to dose in intact animals |
| GHK-Cu | Collagen synthesis modulation, antioxidant, anti-inflammatory | Fibrosis models, wound healing after infarction | 1–2 hours | Copper-dependent activity; toxicity risk at high doses | Underutilized in cardiac research despite strong dermal wound healing data; promising for scar modulation |
| BPC-157 | Angiogenesis, VEGF upregulation, NO pathway modulation | Vascular injury, endothelial dysfunction models | 4–6 hours (estimated) | Limited mechanistic data; most studies in GI and musculoskeletal tissue | Growing interest but needs cardiac-specific validation; current use is exploratory |
| Cartalax (Ala-Glu-Asp) | Gene expression regulation in cardiomyocytes | Aging models, chronic low-grade dysfunction | Unknown (short-chain) | Minimal published mechanistic data; mostly Russian research | Intriguing preliminary data; requires independent replication in Western labs |
This table reflects the current state of peptide research as of 2026. Some sequences have decades of validation, others have compelling preliminary data but lack the mechanistic depth required for FDA investigational new drug applications. Mitochondrial-targeting and natriuretic peptides have the strongest evidentiary foundation; thymosin peptides have reproducible preclinical results but limited human trial data; emerging peptides like BPC-157 and Cartalax require additional characterization before making definitive therapeutic claims.
Key Takeaways
- SS-31 (elamipretide) reduces ischemia-reperfusion infarct size by 40–55% in multiple species by stabilizing cardiolipin and preventing mitochondrial permeability transition. The peptide's D-amino acid stereochemistry is essential for inner membrane selectivity.
- Thymosin beta-4 activates cardiac progenitor cells and reduces fibrotic remodeling when administered within 24–72 hours post-infarction, but shows minimal benefit in chronic heart failure models where fibrosis is already established.
- Brain natriuretic peptide (BNP) levels above 100 pg/mL indicate heart failure with 90% sensitivity; synthetic BNP analogs remain valuable research tools despite limited clinical adoption due to renal safety concerns and receptor downregulation in chronic disease.
- Research peptides targeting mitochondrial function, immune modulation, and hemodynamic regulation represent three mechanistically distinct approaches. Selecting the wrong class for a disease model is the most common protocol design error.
- Batch-to-batch purity consistency and exact amino acid sequencing determine whether peptide research produces replicable data. Substitutions or racemic mixtures can reduce biological activity by 60–70% in receptor binding assays.
What If: Peptides for Cardiac Health Research Scenarios
What If a Peptide Shows Promise in Rodent Models But Fails in Large Animal Studies?
This is the rule, not the exception. Approximately 80% of cardioprotective interventions that succeed in mouse models fail to show equivalent benefit in pigs or primates. Immediately assess three factors: dosing by body weight vs body surface area (mice have 7× higher metabolic rate), administration timing relative to disease stage, and whether the rodent model recapitulates human pathophysiology. Mouse ischemia-reperfusion studies typically use 30–45 minute occlusion times that produce uniform transmural infarcts; human infarctions are heterogeneous with viable islands of tissue that respond differently to peptide therapy. If your peptide worked in mice but failed in pigs, repeat the experiment with dose escalation and confirm plasma levels match rodent studies. Pharmacokinetic scaling is where most translation attempts break down.
What If Storage Temperature Fluctuations Occur During Shipping or Laboratory Transfer?
Any temperature excursion above 8°C for lyophilized peptides or above 4°C for reconstituted solutions risks irreversible conformational changes that neither visual inspection nor basic analytical methods detect. SS-31's mitochondrial-targeting depends on precise charge distribution. Heat-induced aggregation or partial deamidation reduces membrane permeability without changing molecular weight on mass spectrometry. If cold chain integrity is uncertain, run a functional assay (cardiomyocyte viability under oxidative stress, receptor binding affinity) before committing to a full protocol. We've reviewed failed replication attempts where the peptide batch was chemically pure but biologically inactive due to shipping mishandling.
What If You Need to Compare Peptide Therapy to FDA-Approved Cardiovascular Drugs?
Design a three-arm study: peptide alone, standard-of-care drug alone, and combination therapy. Most peptide mechanisms are orthogonal to small-molecule drugs. SS-31 acts on mitochondria while beta-blockers reduce sympathetic drive; thymosin beta-4 modulates immune responses while ACE inhibitors block angiotensin signaling. The most informative research question isn't whether the peptide outperforms existing drugs (it rarely will in aggregate endpoints like mortality) but whether it provides additive benefit or addresses a mechanism that current therapies miss entirely. Frame your hypothesis as mechanism validation, not drug replacement.
What If Preliminary Data Suggests a Peptide Worsens Outcomes in a Subgroup?
Stop and characterize the subgroup before modifying the protocol. Natriuretic peptides can cause hypotension in patients with preserved ejection fraction and normal filling pressures. Giving BNP to diastolic heart failure patients without volume overload produces harm, not benefit. Similarly, immune-stimulating peptides like thymosin alpha-1 may worsen autoimmune-mediated myocarditis even as they improve sepsis-related cardiac depression. Heterogeneity in treatment response is itself a research finding. It identifies which pathophysiological mechanism drives disease in that subset.
The Mechanistic Truth About Peptides for Cardiac Health Research
Here's the honest answer: most peptides studied in cardiac research will never become FDA-approved drugs, and that's not a failure. It's a misunderstanding of their purpose. Peptides are research tools first and therapeutic candidates second. Their value lies in dissecting mechanisms that can't be studied with conventional pharmacology: organelle-specific signaling, spatiotemporal dynamics of repair vs fibrosis, and receptor pathways that lack small-molecule ligands. SS-31 taught cardiovascular researchers more about mitochondrial permeability transition than any previous intervention, not because it's a perfect drug but because it's the only tool that acts at the inner membrane with sufficient selectivity to isolate cardiolipin's role.
The translational gap between preclinical peptide studies and human therapeutics is real. Poor oral bioavailability, rapid proteolytic degradation, and manufacturing costs that exceed small molecules by 10–100× are legitimate barriers. But those limitations don't diminish research value. TB-500's ability to activate cardiac progenitor cells revealed that adult hearts contain repair-capable stem cells, a finding that reshaped regenerative cardiology even though TB-500 itself isn't a clinical therapy. The mechanistic insights from peptide research inform drug design, gene therapy targets, and device-based interventions that eventually do reach patients.
What peptides demand in return is intellectual honesty about experimental design. Using incorrect stereoisomers, dosing without pharmacokinetic data, or applying acute injury peptides to chronic disease models produces noise that wastes funding and delays real progress. The difference between transformative peptide research and irreproducible noise is methodological rigor. Exact sequencing, verified purity, appropriate disease models, and mechanistic endpoints that map to human pathophysiology.
Cardiac research in 2026 has access to peptide tools that didn't exist a decade ago. Mitochondrial-targeting sequences reach organelles no drug could access. Immune-modulatory peptides dissect inflammation from tissue repair. Natriuretic analogs isolate hemodynamic variables that were previously confounded. Those capabilities come with a responsibility to use them correctly. Not as miracle cures, but as precision instruments that answer specific mechanistic questions other methods cannot.
If your research requires peptides with verified amino acid sequencing, batch-consistent purity above 98%, and cold-chain integrity from synthesis through delivery, every compound in the Real Peptides collection meets those standards. The difference between data that gets cited and data that gets questioned often comes down to the quality of the tools you start with.
Frequently Asked Questions
How do mitochondrial-targeting peptides like SS-31 differ from traditional antioxidants in cardiac research?
▼
SS-31 (elamipretide) doesn’t scavenge reactive oxygen species directly — it prevents the mitochondrial dysfunction that generates them in the first place. The peptide binds cardiolipin on the inner mitochondrial membrane to stabilize respiratory chain supercomplexes, preventing cytochrome c release and the permeability transition that triggers apoptosis. Traditional antioxidants like vitamin E or CoQ10 neutralize ROS after they form but don’t address the upstream cause: cardiolipin peroxidation during ischemia-reperfusion injury. This mechanistic difference explains why SS-31 reduces infarct size by 40–55% in animal models while antioxidant supplements consistently show no benefit in clinical trials.
Can peptides be used in long-term chronic heart failure models or only acute injury studies?
▼
Peptide efficacy depends on mechanism and disease stage. Mitochondrial-targeting peptides like SS-31 work best in acute ischemia-reperfusion injury when administered within the first hour of reperfusion — they prevent damage but don’t reverse existing dysfunction. Thymosin beta-4 must be given within 24–72 hours post-infarction to influence the repair-versus-fibrosis decision; it shows minimal benefit in established chronic failure where remodeling is complete. Natriuretic peptides and some experimental sequences like Cartalax have been studied in chronic models, but most cardiac research peptides target acute pathophysiology rather than long-term disease management.
What is the cost difference between research-grade peptides and conventional cardiovascular research compounds?
▼
Custom-synthesized research peptides cost $150–$800 per 5–10mg depending on sequence complexity and purity requirements, compared to $50–$200 for equivalent doses of small-molecule cardiovascular drugs like beta-blockers or ACE inhibitors. The price reflects solid-phase peptide synthesis costs, HPLC purification, and mass spectrometry verification on every batch. For budget-constrained studies, this means peptide experiments require careful dose justification and often smaller animal cohorts than traditional pharmacology studies — but the mechanistic specificity frequently justifies the additional cost when the research question requires organelle-level or receptor-selective intervention that small molecules cannot provide.
What are the signs that a peptide batch has degraded or lost biological activity?
▼
Visual inspection is unreliable — degraded peptides often remain clear and colorless in solution. The only definitive test is functional assay: for cardioprotective peptides, run a cardiomyocyte viability assay under oxidative stress or measure receptor binding affinity compared to a known-good reference batch. Chemical purity by HPLC can remain above 95% even when biological activity drops 50–70% due to deamidation, oxidation of methionine residues, or disulfide bond scrambling in cysteine-containing sequences. Temperature excursions above 8°C for lyophilized peptides or above 4°C for reconstituted solutions are the most common cause of degradation. If storage conditions were compromised at any point from synthesis to use, assume the batch is suspect until functional testing proves otherwise.
Are there cardiac research peptides with oral bioavailability or do all require injection?
▼
Nearly all peptides for cardiac health research require parenteral administration — intravenous, intraperitoneal, or subcutaneous injection in animal models. Proteolytic enzymes in the GI tract (pepsin, trypsin, chymotrypsin) rapidly degrade unmodified peptides into inactive amino acids before systemic absorption occurs. Some experimental approaches improve oral bioavailability: PEGylation (attaching polyethylene glycol chains), D-amino acid substitution, cyclization, or encapsulation in lipid nanoparticles — but these modifications often alter the biological activity being studied. As of 2026, no cardiac research peptide has reliable oral bioavailability in unmodified form, which is one reason peptide therapeutics remain challenging to translate from research to clinical use despite strong preclinical efficacy data.
How does thymosin beta-4 promote cardiac repair differently from growth factors like VEGF?
▼
Thymosin beta-4 acts through multiple pathways simultaneously: it sequesters G-actin to enable cell migration, activates integrin-linked kinase signaling to promote progenitor cell differentiation, upregulates VEGF expression (rather than acting as VEGF itself), and reduces TGF-β1 to limit fibrotic remodeling. Exogenous VEGF administration, by contrast, stimulates angiogenesis through a single receptor pathway but doesn’t influence progenitor cell activation or the fibrosis-versus-repair balance. In post-infarction models, TB-500 produces both increased capillary density and reduced collagen deposition, whereas VEGF alone increases vascularity but often worsens edema and doesn’t prevent scar formation. This multi-target mechanism makes TB-500 a more comprehensive research tool for studying cardiac repair, though it also makes isolating individual pathway contributions more complex.
Why do natriuretic peptides like BNP work in acute heart failure but not chronic management?
▼
Chronic heart failure causes downregulation of guanylyl cyclase receptors (GC-A) and upregulation of neprilysin, the enzyme that degrades natriuretic peptides — creating acquired resistance to both endogenous and exogenous BNP. Acute decompensated heart failure patients still have functional receptors and normal neprilysin activity, so exogenous BNP produces the expected vasodilation and natriuresis. This is why sacubitril/valsartan (Entresto) succeeded where nesiritide monotherapy didn’t: blocking neprilysin restores natriuretic peptide activity in chronic patients who have elevated endogenous levels but rapid degradation. For research applications, this means BNP analogs are most informative in acute hemodynamic studies or early-stage heart failure models before receptor adaptation occurs.
What is the appropriate control group when testing a novel cardiac peptide in animal models?
▼
Use vehicle-only controls matched to your peptide formulation — if your peptide is dissolved in saline with 0.1% BSA, your control group receives saline with 0.1% BSA at the same volume and administration schedule. For mechanisms with existing pharmacological modulators, include a positive control arm using the standard drug (e.g., SS-31 studies should include a cyclosporine A group since CsA is the reference mitochondrial permeability transition inhibitor). Sham surgery controls are essential in ischemia-reperfusion models to distinguish peptide effects from procedural trauma. Never compare peptide-treated disease models to healthy untreated animals — that conflates disease severity with treatment effect and is the most common statistical error in cardiac research design.
Can peptides like SS-31 or TB-500 be combined with gene therapy or cell transplant approaches?
▼
Yes, and combination approaches often produce synergistic effects that neither intervention achieves alone. SS-31 pretreatment improves survival of transplanted stem cells by reducing oxidative stress in the host tissue microenvironment — studies show 2–3× better cell engraftment when mitochondrial-targeting peptides are administered before and immediately after cell injection. TB-500 enhances viral vector transduction efficiency in cardiac gene therapy by promoting cell membrane permeability and reducing inflammatory responses that clear vector particles. The mechanistic rationale is strong: peptides address the hostile ischemic/inflammatory environment while gene therapy or cell transplant provides regenerative capacity. Most published combination studies use peptides in the acute phase (first 24–72 hours) followed by regenerative intervention once tissue conditions stabilize.
What purity level is required for reproducible cardiac peptide research?
▼
Minimum 95% purity by HPLC, with 98%+ preferred for mechanistic studies where minor contaminants could confound interpretation. Mass spectrometry confirmation of the correct molecular weight is essential but insufficient — it only verifies the primary sequence, not stereochemistry or post-translational modifications. For peptides with D-amino acids (like SS-31), chiral HPLC or circular dichroism spectroscopy should confirm stereoisomer purity, since L-amino substitutions pass standard mass spec but lose biological activity. Counter-ion content matters too: acetate salts are preferable to trifluoroacetate (TFA) salts for peptides used in cell culture, as residual TFA can be cytotoxic at concentrations that don’t affect chemical purity measurements. Every batch we produce at Real Peptides includes both HPLC chromatograms and mass spectrometry data; purity below 98% triggers remanufacturing rather than sale.
